The ability to identify factors that predict efficacy of anti–tumor necrosis factor (TNF) agents is crucial if clinicians are to optimize treatment and minimize side effects and costs.
Over the past 20 years, the use of anti—tumor necrosis factor (TNF) agents has revolutionized the treatment of patients with inflammatory bowel disease (IBD) by allowing them to avoid the use of steroids, promoting mucosal healing, reducing hospitalizations and surgeries, and dramatically improving quality of life. However, primary nonresponse to these drugs or loss of response (LOR) over time due to immunogenicity or treatment-related side-effects are a concern.
Nonresponse to anti-TNF therapy occurs in 20% to 40% of patients in clinical trials and in 10% to 20% of patients in real-world scenarios; the incidence of secondary LOR ranges from 23% to 46% a year after treatment initiation. Thus, the abililty to identify factors that predict efficacy of these drugs is crucial if clinicians are to optimize treatment and minimize side effects and costs.
To this point, studies investigating predictive factors have produced controversial results, according to a review by Loris Riccardo Lopetuso, MD, PhD, and colleagues, published in International Journal of Molecular Sciences. The authors undertake this goal through a literature search on the predictive factors of the short- and long-term benefits of anti-TNF therapy in IBD patients, evaluating multiple patient-, disease-, and treatment-related factors for infliximab, adalimumab, golimumab, and certolizumab pegol in both controlled clinical trials and real-world studies.
The authors found the following factors to be predictive of response to anti-TNF treatment in clinical practice:
Patient-related factors:
Disease-related factors:
Treatment-related factors:
The review also lists factors that could be predictive of response to anti-TNF therapy, but that are not yet available in clinical practice. These factors, which could be seen in controlled trials, include genetic variants of particular genes in patients with CD.
“Clearly, in the future, the creation of specific algorithms with the combination of multiple variables could deeply improve their predictive baseline strength before starting [anti-TNF] agents,” the researchers note. “At the same time, in the era of precision medicine, newly diagnosed IBD patients will need to have their genetic, microbiome, and immune characteristics measured at time 0, then matched to the most appropriate biological or immunosuppressive treatment based on likelihood of response/adverse effects.”
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.